Literature DB >> 22360448

Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats.

Alice Zachařová1, Michal Siller, Alena Spičáková, Eva Anzenbacherová, Nina Skottová, Pavel Anzenbacher, Rostislav Večeřa.   

Abstract

The aim was to investigate whether rosuvastatin affect rat cytochrome P450 (CYP) 2C11 and CYP2C6. CYP2C11 and CYP2C6 are considered as counterparts of human CYP2C9, which metabolizes many drugs including S-warfarin, diclofenac or ibuprofen. The male Wistar rats were fed standard laboratory diet (STD) or high cholesterol diet (HCD, 1% of cholesterol, 10% of lard fat) for 21 days. Rosuvastatin administration in STD (0.03% w/w) resulted in decreased mRNA expression of CYP2C11 as well as of CYP2C6 (here significant) and in a significant decrease of the respective protein expression as well as of the enzyme activity of both CYP2C forms. When rosuvastatin was administered in the HCD, the mRNA expression of both CYP2C forms was significantly lowered; the protein and activity parameters did not show significant changes. These results suggest that CYP2C11 as well as CYP2C6 expression and activity are negatively affected by rosuvastatin and may be modulated by high cholesterol high fat diet. Therefore, it should be taken into consideration that drugs metabolized by CYP2C9 in human could interact with rosuvastatin, as it has been already suggested for warfarin (rosuvastatin has increased its anticoagulant effect in human), and for telmisartan, sildenafil and glimepiride.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22360448     DOI: 10.3109/00498254.2012.661099

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  4 in total

1.  Pharmacokinetics and hepatic uptake of gliquidone affected by Huangqi injection.

Authors:  Fan Zhang; Yuhui Wei; Yan Zhou; Dan Wang; Liting Zhou; Jianping Zhang; Xinan Wu
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-10-02       Impact factor: 2.441

2.  Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?

Authors:  Choon Ok Kim; Eun Sil Oh; Hohyun Kim; Min Soo Park
Journal:  Drug Des Devel Ther       Date:  2017-02-23       Impact factor: 4.162

3.  A Mechanism of O-Demethylation of Aristolochic Acid I by Cytochromes P450 and Their Contributions to This Reaction in Human and Rat Livers: Experimental and Theoretical Approaches.

Authors:  Marie Stiborová; František Bárta; Kateřina Levová; Petr Hodek; Heinz H Schmeiser; Volker M Arlt; Václav Martínek
Journal:  Int J Mol Sci       Date:  2015-11-18       Impact factor: 5.923

4.  Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo.

Authors:  Helena Dračínská; František Bárta; Kateřina Levová; Alena Hudecová; Michaela Moserová; Heinz H Schmeiser; Klaus Kopka; Eva Frei; Volker M Arlt; Marie Stiborová
Journal:  Toxicology       Date:  2016-02-01       Impact factor: 4.221

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.